TGFB1 and cancer: When combining specific TGF-β1 inhibitor SRK181-mIgG1 with anti–PD-1 antibody in multiple mouse models of cancer, the combo therapy significantly induced the intratumoral infiltration of CD8+ T cells with less dose-limiting toxicology (160).